20
Jul
2021
Rivus Gets $35M to Alter Mitochondria for T2D, NASH, Heart Failure & More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jul
2021
Investing at the Nexus of Biology & Technology: Jenny Rooke on The Long Run
Today’s guest on The Long Run is Jenny Rooke. Jenny is the founder and managing partner of San Francisco-based Genoa Ventures. I’ve been wanting to invite Jenny on the podcast for a while. Back in 2018, I profiled her as one of “Nine VCs Who Matter, But You Never Read About.” As I wrote then: “VCs take on lots of... Read More
19
Jul
2021
From Delta…to Omega?
I hope you are all enjoying your summer break with (finally) being able to see friends and family (and fine food NOT from a delivery service). You are? Great! Now let me spoil some of that for you. This pandemic is not over I understand the inclination to consider the pandemic behind us. In large parts of the US /... Read More
15
Jul
2021
Payers Revolt Against Biogen’s Aduhelm, FDA Credibility Crisis, and a Prime Financing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Jul
2021
One-and-Done Gene Editing: A Feature or Flaw?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jul
2021
Verge Genomics Strikes Deal with Lilly to Validate New Targets for ALS
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jul
2021
Biogen’s Perilous Path, Intellia’s In Vivo Milestone, & Holiday Financings
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jun
2021
Immunocompromised People Are Vulnerable to COVID-19. We Owe Them Some Answers
As fully vaccinated citizens in our country and around the globe begin to dip their toes in the waters of a post-vaccination world, there are two groups that deserve greater consideration: immunosuppressed or immunocompromised people. This is not a small group of people. Estimates are that about 6.2 percent of adults ages 18-64 in the US are living with weakened... Read More
29
Jun
2021
Lab Supply Shortages Persist, Slowing Down Everyday Experiments
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2021
Lander Pushes ARPA-H, Lilly Follows Fast in Alzheimer’s, & Wyden Moderates on Price
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2021
The Other Half: Decentralized Research is The Path to All-Inclusive Medicine
More than half of the U.S. population is projected to be “other than non-Hispanic white” by 2045. If the current clinical research process doesn’t adapt to these changing population demographics, the life sciences industry will continue developing drugs and devices that are only shown to work for a select few, leaving out the “other half.” Despite efforts, including those from... Read More
24
Jun
2021
EQRx, Exscientia Team Up to Accelerate R&D for Lower-Priced, Better Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jun
2021
F-Prime Leads $60M Bet on Adela, Scanning the Methylome for Early Signs of Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jun
2021
Third Rock-Backed Abata Secures $95M for T-reg Cell Therapy Against MS
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jun
2021
Biopharma’s Racial Justice Work is a Start. But More Needs to Happen
Biopharma leaders have pledged to make their companies more diverse and inclusive. MassBio created an open letter on culture, recruitment, development, sustainability and accountability that has been signed by presidents and CEOs of more than 200 member companies. Large and small companies have described some of their specific efforts in public. Bristol-Myers Squibb aims to double the number of executive... Read More
17
Jun
2021
Novavax Nails Vaccine Trial, CureVac Fails, & Flagship Sails on With $3.4B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jun
2021
On Juneteenth, Honoring 22 Black Biotech Leaders
A few Black people have risen to prominence in biopharma. Ken Frazier, Tony Coles, Rob Perez and Ted Love are among the most visible. But there are many other Black leaders in the industry who are making important contributions to the science and business of human health. Today, let’s recognize the Juneteenth holiday coming up June 19. It’s a celebration... Read More
17
Jun
2021
Versant, RA Bet $47M on LENZ Therapeutics to Restore Near Vision in Middle Age
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Jun
2021
After Devastating New Study, Is There A Future For Workplace Wellness – And Has Peloton Figured It Out?
This is a story about the tension between what we desperately want to believe and what the data suggest we should believe, and — surprise! — this isn’t about the contentious recent approval of the Biogen drug aducanumab for Alzheimer’s Disease. Rather, it’s about a powerful and important study just published in Health Affairs, examining the outcomes of a workplace wellness program in a... Read More
15
Jun
2021
Mentoring Young Scientists: Jay Bradner and Andy Plump on The Long Run
This episode of The Long Run is a little different. I invited a couple previous guests on The Long Run to discuss a specific issue: How the industry can do a better job of mentoring young scientists, and creating on-ramps to careers in the biopharma industry for people from underrepresented groups. Jay Bradner, the president of the Novartis Institutes for... Read More